Table 2.

Priority issues in clinical research on first-line immunotherapy in ECOG PS 2 patients with NSCLC

Issue	Priority
Inclusion of PS 2 patients in upcoming clinical trials evaluating immune-oncology agents in NSCLC (PS 2 versus 0-1 as stratification factor in phase III studies or different cohort studies)	High
Studies on single-agent chemotherapy plus ICIs	High
Studies on platinum-based chemotherapy with personalized/attenuated doses plus ICI	High
Studies on dual anti-PD-1/PD-L1 plus anti-CTLA-4 in PS 2	Medium
Studies on duration of ICI treatment	Medium
Studies on alternative schedules/doses of ICI treatment	Medium
Studies on single-agent immunotherapy versus platinum-based doublet chemotherapy plus immunotherapy in PD-L1 ≥50%	Medium
Biological and translational studies on blood biomarkers to evaluate immune activation in PS 2 patients receiving immunotherapy	Low

CTLA-4, cytotoxic T-lymphocyte-associated antigen 4; ECOG, Eastern Cooperative Oncology Group; ICI, immune checkpoint inhibitor; NSCLC, non-small-cell lung cancer; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; PS, performance status.